Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL
Experts discuss clinical features and risk factors in navigating the decision between autologous stem cell transplant (ASCT) and chimeric antigen receptor T-cell (CAR T) therapy for patients with relapsed/refractory large B-cell lymphoma (R/R LBCL).
Video Player is loading.
EP: 1.Brief Overview of Current Treatment Landscape and Unmet Needs in R/R Large B-Cell Lymphoma
EP: 2.Three-Year Follow-Up From Phase 3 TRANSFORM: Study Overview and Key Efficacy Data
EP: 3.Long-Term Efficacy and Real-World Outcomes With Liso-cel
EP: 4.Patient Selection and Timing Considerations for CAR T Therapy
EP: 5.Impact of Manufacturing and Treatment Timing on Patient Outcomes for CAR T in R/R LBCL
Now Viewing
EP: 6.Clinical Features and Risk Factors: Navigating ASCT vs CAR T Therapy Decisions in R/R LBCL
EP: 7.TRANSFORM Safety Summary
EP: 8.Safety Management and Monitoring Protocols for Liso-cel
EP: 9.Future Directions and Key Insights in LBCL Treatment
Recent Videos
CAR T vs Bispecifics: Expanding CAR T Reach in B-Cell Malignancies
Looking Ahead in HER2+ mBC: Unmet Needs, Future Perspectives and Highlights From ASCO 2025
Real-World Use, Outpatient Dosing and Transitions of Care in Academic and Community Settings
Expert Insights: Later-Line Treatment Strategies for HER2+ Metastatic Breast Cancer
Debate: Sequencing Therapies for LR-MDS: ESA First vs Luspatercept First
Tucatinib Triplet Therapy: Efficacy, Safety and Clinical Decision-Making
A Review of Outpatient Step-Up Dosing for Talquetamab in R/R MM
Debate: Inflection Point for LR-MDS Therapy: Serum EPO >200 U/L vs Serum EPO >500 U/L
PERSEUS Trial: MRD Negativity
PERSEUS Trial: Design/Baseline Characteristics
Related Content
